Loading organizations...
§ Private Profile · Illkirch, Alsace, France
Biopharmaceutical company developing small-molecule therapies for cancer and inflammation, focused on GPCR targets.
Kainova Therapeutics, led by CEO Sean A. MacDonald and based in Montréal, Canada, develops small-molecule therapies targeting G protein-coupled receptors (GPCRs) for cancer and inflammation. Leveraging its proprietary bioSens-All technology, the company advances clinical-stage candidates like DT-7012 and DT-9046 by studying GPCRs in their native states. With 49 employees, Kainova has secured approximately $90 million USD in venture capital, including a $42 million USD Series A in 2022 and a $32 million CAD Series B first close in 2026. This substantial funding is complemented by nearly $100 million USD in non-dilutive grants, with significant support from investor AdMare BioInnovations. The organization, founded in 2008, rebranded from Domain Therapeutics in early 2026. Its business model centers on venture capital-funded biopharmaceutical company, also secures non-dilutive funding through grants.
Kainova Therapeutics has raised $2.4B across 2 funding rounds.
Kainova Therapeutics, formerly Domain Therapeutics, changed its name on January 12, 2026, to better align with its evolving scientific ambitions and clinical focus, particularly in the field of immuno-oncology.
Kainova Therapeutics is funded by 26 investors, with adMare BioInnovations and Viva BioInnovator identified as some of the most recent investors supporting the company's initiatives.
Kainova Therapeutics, formerly Domain Therapeutics, changed its name on January 12, 2026, to better align with its evolving scientific ambitions and clinical focus, particularly in the field of immuno-oncology.
Kainova Therapeutics is funded by 26 investors, with adMare BioInnovations and Viva BioInnovator identified as some of the most recent investors supporting the company's initiatives.
Kainova Therapeutics has raised $2.4B across 2 funding rounds. Most recently, it raised $2.4B Series B in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 10, 2026 | $2.4B Series B | Investissement Québec | 3B Future Health Fund, Admare Bioinnovations, CTI Life Sciences Fund, Panacea Venture, Schroders Capital, Seido Capital, Seventure Partners, Turenne Capital, Viva BioInnovator | Announced |
| Feb 9, 2026 | $23.5M Series B | Investissement Québec | 3B Future Health Fund, AdMare BIO Innovations, CTI Life Sciences Fund, Panacea Venture, Schroders Capital, Seido Capital, Seventure Partners, Turenne Capital, Viva BioInnovator | Announced |
Kainova Therapeutics, previously known as Domain Therapeutics, is a biopharmaceutical company specializing in the discovery and development of small molecules that modulate G-coupled protein receptors (GPCRs). The company officially adopted the name Kainova Therapeutics on January 12, 2026, marking a new chapter in its strategic direction and clinical objectives, particularly within immuno-oncology.
The company's core scientific approach centers on leveraging GPCR targets for therapeutic intervention. GPCRs are a large family of cell surface receptors that play critical roles in various physiological processes, making them attractive targets for drug development. Kainova Therapeutics aims to develop novel therapies by precisely modulating the activity of these receptors.
As a clinical-stage entity, Kainova Therapeutics is actively advancing a pipeline of drug candidates. Its focus on immuno-oncology highlights an effort to develop treatments that can harness the body's immune system to fight cancer, utilizing its expertise in GPCR modulation to achieve this goal.
The company is headquartered in Illkirch, Alsace, France, and operates as a privately held organization. Its development efforts are supported by a diverse group of investors, with 26 entities contributing to its funding. Notable recent investors include adMare BioInnovations and Viva BioInnovator, indicating continued financial backing for its research and development initiatives.